Skip to main content
Premium Trial:

Request an Annual Quote

Six RNAi-Related Patent Applications Published by the USPTO: Apr 15, 2005

Premium

Title: Methods and Products for Expression of microRNAs

Number: 20050075492.

Filed: Aug. 6, 2004.

Inventor: Chang-Zheng Chen, Whitehead Institute.

The patent application, its abstract states, "relates to microRNAs, methods of producing microRNAs, and methods for using microRNAs."

Specifically, the patent application claims "a precursor microRNA molecule comprising an isolated nucleic acid." This nucleic acid comprises "a stem-loop structure, wherein a microRNA sequence is incorporated into a stem of the stem-loop structure, and a microRNA flanking sequence flanking at least one end of the stem-loop structure," the patent application states.


Title: Inhibition of Syk Kinase Expression.

Number: 20050075306.

Filed: July 1, 2004.

Lead Inventor: Alan Schreiber, University of Pennsylvania.

The invention "relates, in general, to Syk kinase and, in particular, to a method of inhibiting Syk kinase expression using small-interfering RNA," the patent application's abstract states.

The application specifically claims "a method of inhibiting expression of Syk kinase in a cell comprising introducing into said cell small-interfering RNA molecules that direct cleavage of a target Syk kinase mRNA sequence present in said cell thereby effecting said inhibition." The application further claims the inhibition of Syk kinase expression using siRNAs in a patient suffering from an inflammatory condition of the bronchi, lungs, eyes, bladder, or skin.


Title: RNA Interference-Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid.

Number: 20050075304.

Filed: Jan. 12, 2004.

Lead Inventor: James McSwiggen, Sirna Therapeutics.

"The … invention concerns methods and reagents useful in modulating vascular endothelial growth factor (VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D) and/or vascular endothelial growth factor receptor (e.g., VEGFr1, VEGFr2 and/or VEGFr3) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications," the patent application's abstract states. "Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid, short-interfering RNA, double-stranded RNA, microRNA , and short-hairpin RNA molecules capable of mediating RNA interference against VEGF and/or VEGFr gene expression and/or activity. The small nucleic acid molecules are useful in the diagnosis and treatment of cancer, proliferative diseases, and any other disease or condition that responds to modulation of VEGF and/or VEGFr expression or activity."


Title: Adenoviral VA1 Pol III Promoter System for RNAi Expression.

Number: 20050074887.

Filed: July 30, 2003.

Lead Inventor: John Rossi, Beckman Research Institute.

The patent application covers an adenoviral VA1 Pol III expression system for RNAi expression, its abstract states.


Title: Detection of Small Nucleic Acids.

Number: 20050074788.

Filed: Dec. 18, 2003.

Lead Inventor: James Dahlberg, Third Wave Technologies.

"The … invention relates to compositions and methods for the detection and characterization of interfering RNAs such as microRNAs and small-interfering RNAs and other short nucleic acid molecules," the patent application's abstract states. "More particularly, the … invention relates to improved methods for the detection and quantitation of interfering RNA expression. The … invention further provides for the detection of variants and types of miRNAs and siRNAs."


Title: Compositions and Methods for Inhibiting Expression of a Mutant Gene.

Number: 20050074757.

Filed: March 7, 2003.

Lead Inventor: Roland Kreutzer, Ribopharma (Alnylam Europe)

The invention "relates to a double-stranded ribonucleic acid for inhibiting the expression of a mutant gene, comprising a complementary RNA strand having a complementary region that is substantially complementary to a portion of the mutant gene, and which is partially complementary to the corresponding wild-type gene," the patent application's abstract states "The invention further relates to a pharmaceutical composition comprising the dsRNA and a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for inhibiting the expression of a target mutant gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target mutant gene, as well as methods for treating diseases caused by the expression of the target gene."